# Imcyse SA: Research, Liege, Belgium

> Imcyse SA: Imcyse SA is a clinical-stage biopharmaceutical company located in Liège, Belgium. Based in Liege, Belgium. Founded 2011.

Source: https://millionrounds.com/startup/imcyse-sa (Millionrounds; every figure on the page links to its filing or article)

Belgium · [Research startup](https://millionrounds.com/companies)

# Imcyse SA

Imcyse SA is a clinical-stage biopharmaceutical company located in Liège, Belgium.

Funding reported Last round: Series B

Research Liege, Belgium

Company summary

- **Founded:** 2011 15 years old
- **Team:** 5 1 to 10 people
- **Funding reported:** 55.9M as listed, currency not stated
- **Last round:** Series B Feb 2021

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Imcyse SA has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Imcyse SA

Imcyse SA is a clinical-stage biopharmaceutical company located in Liège, Belgium.

Founded in 2010 as a spin-off from the Catholic University of Leuven, Imcyse focuses on developing antigen-specific immunotherapies to treat severe chronic autoimmune diseases using its proprietary ImotopeTM technology platform. The company aims to transform the treatment landscape for these conditions by preventing, treating, and potentially curing diseases that are currently underserved by existing therapies. Imcyse's core technology involves administering specifically modified peptides, known as ImotopesTM, to generate cytolytic CD4 T-cells. These cells target and eliminate the immune cells responsible for damaging the affected organs, aiming to halt disease progression without compromising overall immune function. The company has a robust pipeline that includes clinical programs for Type 1 Diabetes and Multiple Sclerosis, as well as pre-clinical programs for conditions like Neuromyelitis Optica and Celiac Disease. Imcyse is committed to addressing the needs of patients suffering from severe autoimmune diseases where current treatments primarily manage symptoms.

## What company datasets say Imcyse SA raised

Funding, as reported

Reported in all **55.9M** in the source's currency

Rounds **4**

Last round **Series B**

Last round size **23.4M**

Last round date **Feb 2021**

Investors listed **10**

## Founders and team

From Imcyse SA's own website: 11 on the team.

- **Denis Bedoret** Chief Executive Officer
- **Andrew Mackie** Chief Business Officer
- **Gene Mack** Chief Financial Officer
- **Jean Van Rampelbergh** Ph.D, Chief Clinical Development Officer
- **Geoffrey Gloire** Ph.D, IP Director
- **Luc Vander Elst** TecOps Director
- **Stefan Yee** Director – representing AS partners - Biogenosis
- **Stijn Van Rompay** Director – representing SVR Invest – Biogenosis
- **Thomas Taapken** Ph.D., Chairman of the Board
- **Vincent Carlier** Ph.D, R&D Director Immunology
- **Vincent G. Brichard** Ph.D., Director – representing LSP 6 Holding

## On a portfolio page

Investors who name them

- [Epimède](https://millionrounds.com/fund/epimede)

Each firm lists Imcyse SA on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

autoimmune disease research health care biotechnology research immune system modulation autoimmune disease platform imotope platform peptides autoantigen targeting medical research autoimmune disease control autoimmune attack autoimmune disease immune system repair clinical-stage biopharmaceutical autoimmune disease biomarkers autoimmune disease treatment autoantigen presentation

Built with from their website

Google Maps OVHcloud Apache Viewport Meta Veeam Windows Server VMware vCenter YOOtheme Microsoft Exchange Microsoft Azure

+8 more

Microsoft 365 Apps & Services Mobile Friendly vSphere jQuery RSS VMware ESXi Joomla Uikit

- **Sector:** Research
- **Industry code:** NAICS 541714, 325414, SIC 2834, 2836
- **Region:** Walloon Region
- **Revenue:** 4M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/imcyse)

## Research in Belgium

Startups like it

- [**Fyteko** Anderlecht · founded 2014 *Raised*](https://millionrounds.com/company/fyteko)
- [**Cellaïon** Mont-Saint-Guibert · founded 2021](https://millionrounds.com/startup/cella-on)
- [**Precirix** Jette · founded 2014](https://millionrounds.com/startup/precirix)
- [**Full-Life Technologies** Gembloux · founded 2021](https://millionrounds.com/startup/full-life-technologies)
- [**Augustine Therapeutics** Leuven · founded 2019](https://millionrounds.com/startup/augustine-therapeutics)
- [**NOVADIP Biosciences S.A.** Mont-Saint-Guibert · founded 2013](https://millionrounds.com/startup/novadip-biosciences-s-a)
- [**EyeD Pharma** Seraing · founded 2012](https://millionrounds.com/startup/eyed-pharma)
- [**atbtherapeutics** Marche-en-Famenne · founded 2018](https://millionrounds.com/startup/atbtherapeutics)

## Is this your company?

Add your raise, your deck and your story, and put Imcyse SA in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)